Angiodynamics Inc. (ANGO)
AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for AngioDynamics (ANGO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
AngioDynamics (ANGO) Upgraded to Buy: Here's Why
AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down
AngioDynamics tops estimates as revenue rises and losses narrow, driven by Med Tech demand, even as gross margin slips.
AngioDynamics Growing, But With More Noise Than The Street Likes
AngioDynamics is undervalued but remains a volatile, mixed-execution med tech story requiring patient investors. The Med Tech business continues to show robust growth—AlphaVac up 47%, NanoKnife up 21%—but margins and legacy Medical Devices drag on valuation. Q4 guidance disappointed due to increased R&D, inventory build, and ongoing tariff costs, though revenue guidance was raised.
AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript
AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript
AngioDynamics (ANGO) Reports Q3 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to earnings of $0.03 per share a year ago.
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
ANGO stock is buoyed by strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer and broad Med Tech growth supporting margins.
ANGO Expands NanoKnife in Europe for Multi-Organ Tumor Ablation
AngioDynamics expands NanoKnife's EU indications to liver, pancreas, kidney and prostate tumors, broadening its oncology reach and growth runway.
Does AngioDynamics (ANGO) Have the Potential to Rally 92.15% as Wall Street Analysts Expect?
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 92.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
ANGO stock is buoyed by strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer, and broad Med Tech growth supporting margins.
AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
3 MedTech Stocks Benefiting From Favorable Product Mix Shifts
ANGO, BSX and MDT are showing earnings quality improve as higher-margin products take share, supporting margins and durable growth across MedTech.
